Physician profile
Thomas J Way
NPI 1386897346
$3,489.48
in general payments reported to CMS, 2019-2025
25 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 86% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $372 · 2021: $457 · 2022: $166 · 2023: $569 · 2024: $144 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Travel and Lodging: $582 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.82 |
| Travel and Lodging | $581.92 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $821.80 | 2025 | Inspire |
| Intersect Ent, INC. | $489.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $437.25 | 2022-2025 | Nucala |
| Acclarent, INC | $380.33 | 2019-2023 | Trudi Nav Cable |
| Genzyme Corporation | $269.65 | 2022-2025 | |
| Integra Lifesciences Corporation | $196.62 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Regeneron Healthcare Solutions, INC. | $184.25 | 2021-2025 | Dupixent |
| Smith+Nephew, INC. | $169.51 | 2019-2023 | Grafix Pl |
| Neurent Medical Limited | $132.08 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Optinose US, INC. | $64.74 | 2021 | |
| Merck Sharp & Dohme LLC | $45.14 | 2021-2025 | Keytruda |
| Stryker Corporation | $41.99 | 2019 | |
| Ethicon US, LLC | $36.98 | 2025 | Harmonic |
| Amgen INC. | $34.00 | 2025 | |
| Seagen INC. | $33.34 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.17 | 2023 | Propel |
| Ambu INC. | $18.63 | 2023 | |
| Kaleo, INC. | $15.21 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.10 | 2019 | |
| Coherus Oncology, INC. | $14.47 | 2021 | |
| Pfizer INC. | $14.42 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.95 | 2019 | |
| Incyte Corporation | $12.54 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.47 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Way listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.